Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Targeting Aging With a Ketone Ester for Function in Frailty

This study aims to find out if a food supplement that contains a naturally occurring substance, ketones, can help to improve strength and general wellness in adults at, or over the age of 65 years who are experiencing a slight decline in their physical function. Participation will involve a screening visit and 4 additional study visits over the course of 20 weeks. After being assessed for eligibility, study participants will be sorted into two groups at random and consume either a ketone or placebo supplement at home every day for 20 weeks. Both study products can cause gastro-intestinal side effects in some individuals. At all study visits, subjects will provide blood samples. At three study visits, subjects will be asked to complete physical performance tests, provide blood, stool and urine samples. They will also complete questionnaires during three study visits to assess physical function, markers of inflammation, and other aspects of general well-being. The study enrolls at three sites across the United States, in California (Buck Institute), Ohio (Ohio State University), and Connecticut (University of Connecticut). The study is coordinated by the San Francisco Coordinating Center (California Pacific Medical Center).

Participants needed: 180
Trial details
Age: 65+Biological sex: AllType: InterventionalSponsor: Buck Institute for Research on AgingUpdated: Mar 13, 2026Locations: 3
Eligibility criteria

Subject is greater than or equal to 65 years of age, inclusive at Screening. [+4]

Subject is non ambulatory. [+23]

Status: Recruiting

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Participants needed: 30
Trial details
Age: 45-65Biological sex: FemaleType: InterventionalSponsor: Buck Institute for Research on AgingUpdated: Sep 8, 2025Locations: 1
Eligibility criteria

Adults identified as female at birth with ovaries present (self-report) [+7]

Surgical menopause (self-report) [+22]

Status: Recruiting

Temporal Investigation of Multimodal Elements

The TIME Study is a research project aiming to understand the body's natural rhythms. The goal is to see how daily and weekly changes in our bodies-from what's happening at a molecular level to data from wearable devices-are connected. What is the study about? This study is trying to create a detailed map of how a person's body changes over time. By looking at information from blood, urine, and other samples, as well as data from smartwatches and other devices, researchers want to learn how our bodies' natural cycles work in healthy older adults. The long-term goal is to use this knowledge to help develop more personalized healthcare in the future. Who can participate? The study is looking for healthy adults, age 55 or older, who have a smartphone and are able to travel to the Buck Institute in Novato, California, for study visits. Participants will be asked to: Attend weekly visits over 11 weeks to provide blood and other samples. Wear health-tracking devices like a smart ring and watch. Use a smartphone app to answer questions about their daily routines. Complete two "challenge" tests, including drinking a glucose solution and exercising on a stationary bicycle. Return for follow-up visits after 6 and 12 months. Are there any risks or benefits? Benefits: There are no direct health benefits for participants. However, the information gained will help scientists create better diagnostic tools and treatments for future generations. Risks: The main risks are minor discomfort from things like blood draws or skin irritation from the wearable devices. All personal information and data are kept private and secure.

Participants needed: 120
Trial details
Age: 55+Biological sex: AllType: ObservationalSponsor: Buck Institute for Research on AgingUpdated: Aug 15, 2025Locations: 1
Eligibility criteria

Healthy adults aged 55 years or older. [+6]

Hospitalization within the last 3 months. [+10]

Status: Recruiting

Molecular Optimization Via Exercise (MOVE)

This study is to investigate characteristics of muscle, blood, and urine samples from older adults (ages 65-80) who are either sedentary or athletes performing at an elite level for their age. This observational study will include bio-specimen collection, as well as physical and cognitive function testing and body composition.

Participants needed: 80
Trial details
Age: 65-80Biological sex: AllType: ObservationalSponsor: Buck Institute for Research on AgingUpdated: Oct 8, 2024Locations: 1
Eligibility criteria

Willing and able to provide consent to take part in the MOVE-1 Main Study. [+10]

Subject requires assistance with any activity of daily living, excluding contine... [+26]